
Aignostics
Founded Year
2018Stage
Series B | AliveTotal Raised
$53.94MLast Raised
$34M | 8 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+155 points in the past 30 days
About Aignostics
Aignostics specializes in AI-powered precision medicine, focusing on the biopharmaceutical industry. The company offers insights by analyzing complex biomedical data, including histopathology, omics, and clinical outcomes, to support drug development and improve patient outcomes. It serves the biopharma sector with solutions for target identification, translational research, trials, and companion diagnostics. It was founded in 2018 and is based in Berlin, Germany.
Loading...
Aignostics's Product Videos


ESPs containing Aignostics
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI drug target identification platforms market includes solutions that leverage AI/ML to identify and validate novel therapeutic targets from multi-modal biological data. These technologies analyze genomics, proteomics, and clinical data to uncover new drug targets and patient stratification strategies. They help pharmaceutical companies prioritize targets and enable precision medicine approac…
Aignostics named as Leader among 15 other companies, including Google, NVIDIA, and Tempus.
Aignostics's Products & Differentiators
R&D
Identify and test novel biomarker / therapy combinations with pharma and biotech, as well as our academic partners.
Loading...
Research containing Aignostics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aignostics in 4 CB Insights research briefs, most recently on Jul 3, 2025.

May 23, 2025
The AI in drug R&D market map
Expert Collections containing Aignostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aignostics is included in 5 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
12,322 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
11,408 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
522 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Digital Health 50
50 items
AI in drug discovery
521 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Aignostics Patents
Aignostics has filed 2 patents.
The 3 most popular patent topics include:
- machine learning
- anatomical pathology
- artificial neural networks

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
11/17/2023 | 9/10/2024 | Staining, Artificial neural networks, Histopathology, Machine learning, Anatomical pathology | Grant |
Application Date | 11/17/2023 |
---|---|
Grant Date | 9/10/2024 |
Title | |
Related Topics | Staining, Artificial neural networks, Histopathology, Machine learning, Anatomical pathology |
Status | Grant |
Latest Aignostics News
May 2, 2025
Regulated Teams Can Remain Compliant and Accelerate Product Innovation by Automating Arduous Manual Tasks Ketryx , the leader in AI-powered compliance for life sciences, announced the launch of the first validated AI agents for regulated industries. This industry-first set of validated agents will transform how highly regulated companies design, develop, and deploy new products to market. Ketryx’s risk-based agents maintain human-in-the-loop oversight for safety-critical decision-making, so regulated teams can leverage the power of AI to generate documentation and accelerate product delivery. “Highly regulated companies face a complicated paradox today: the systems and processes in place to ensure safety also weigh them down to the point where product teams across AI, software, and hardware spend most of their time on documentation and compliance instead of innovation,” said Erez Kaminski, CEO and founder of Ketryx. “We built Ketryx so quality and product development teams can harness the power of AI, a power so impactful it is the equivalent of tens of thousands of round-the-clock workers perpetually sifting through every piece of incoming data to ensure that patient-critical devices receive the most updated software as quickly and responsibly as possible.” These AI agents will address the traditional pain points that regulated teams face when developing products, such as manual documentation, tedious change management processes, and the complexity of fragmented systems. For example, when tens of thousands of requirements, test cases, risks, and quality procedures live in different tools, it’s extremely difficult to control for conflicts, ensure process adherence, and create traceability. “We use Ketryx to analyze risks, find incomplete or missing risks, and trace requirements to the associated risks,” said Nicole Hollauf, Risk and Compliance Manager at Aignostics, a global AI pathology company. “Previously, this process was manual, so Ketryx gives us a repeatable quality process, saves us time, and helps us release faster while also ensuring that we have controls for all risks.” Ketryx’s first available validated agents for safety-critical industries solve for the risk of human error and reduce the time spent resolving conflicts between requirements. In addition, Ketryx is rapidly expanding its set of pre-built AI agents for safety-critical industries with the following agents commercially available and soon to be validated: Complaint Agent streamlines complaint intake, categorizes complaints instantly, and flags critical signals so you can uncover quality issues early Redundancy Detection Agent finds and eliminates duplicate or overlapping items Test Coverage Analysis Agent evaluates and improves test coverage of requirements Anomaly Review Agent analyzes anomalies for accuracy and completeness and suggests improvements Change Request Review Agent analyzes product modifications, traceability, and potential risks and provides recommendations for improvement AI, software, and product teams at highly regulated companies, such as those in the medical device and life science fields, can maximize the power of Ketryx’s AI agents to: Automate Documentation and Traceability: Reduce documentation burden by 90% and shift the team’s time to focus on managing risk and building innovative products. Ketryx’s set of templated and custom-built AI agents can define requirements, suggest change impact, summarize documents like an SRS or SDS, author specifications, suggest traceability links, and create test plans. Benefit from AI-Enhanced Quality and Compliance: Ketryx deeply understands and analyzes a company’s quality management system, compliance records, and product development processes across all connected tools. With Ketryx’s AI agents, team members can routinely identify risks and gaps, get instructions on what actions to take to follow their procedures, detect compliance issues, and surface hidden patterns that might otherwise go unnoticed by humans. Release 10X Faster: Agents operate within a validated environment to accelerate change management, suggest improvements, answer regulatory questions, and generate documentation. Agents always keep a human in the loop for oversight and make it simple to move quickly by providing redlines along with any recommendations and enabling approval with a single click. “Ketryx’s approach addresses the critical bottleneck of documentation and compliance that has historically hindered innovation in regulated industries,” said Holger Mueller, Vice President and Principal Analyst at Constellation Research. “By automating the tedious aspects of documentation while maintaining human oversight and validation, Ketryx’s agents enable organizations to achieve both regulatory compliance and agile development – a combination that has been elusive until now. Companies that leverage these types of AI agents as an added layer of quality review will gain significant competitive advantages in time-to-market without sacrificing safety or compliance.” [To share your insights with us, please write to psen@itechseries.com] PR Newswire, a Cision company, is the premier global provider of multimedia platforms and distribution that marketers, corporate communicators, sustainability officers, public affairs and investor relations officers leverage to engage key audiences. Having pioneered the commercial news distribution industry over 60 years ago, PR Newswire today provides end-to-end solutions to produce, optimize and target content -- and then distribute and measure results. Combining the world's largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions. Prev Post Next Post
Aignostics Frequently Asked Questions (FAQ)
When was Aignostics founded?
Aignostics was founded in 2018.
Where is Aignostics's headquarters?
Aignostics's headquarters is located at Alt-Moabit 73/73A, Berlin.
What is Aignostics's latest funding round?
Aignostics's latest funding round is Series B.
How much did Aignostics raise?
Aignostics raised a total of $53.94M.
Who are the investors of Aignostics?
Investors of Aignostics include High-Tech Grunderfonds, VC Fonds Technologie, Boehringer Ingelheim Venture Fund, Wellington Partners, Mayo Clinic and 8 more.
Who are Aignostics's competitors?
Competitors of Aignostics include Mindpeak and 3 more.
What products does Aignostics offer?
Aignostics's products include R&D and 2 more.
Loading...
Compare Aignostics to Competitors
Aiosyn is a healthtech company focused on developing precision pathology software solutions for the healthcare sector. The company offers AI-powered algorithms that enhance digital pathology workflows and support clinical diagnostics, as well as tools for the identification of pathology-based biomarkers for drug development. Aiosyn primarily serves the healthcare industry, including pathology laboratories and biopharmaceutical companies. It was founded in 2021 and is based in Nijmegen, Netherlands.
Imagene AI specializes in AI-based precision oncology within the healthcare sector, focusing on cancer research and diagnostics. The company offers a SaaS platform that integrates imaging, molecular, and clinical data to support biomarker discovery, trial design, and patient identification. Imagene AI primarily serves the healthcare and oncology research sectors with its diagnostic and treatment solutions. It was founded in 2020 and is based in Miami, Florida.

BioAI focuses on advancing precision medicine through multimodal artificial intelligence within the biopharmaceutical sector. The company offers artificial intelligence (AI) driven services for biomarker discovery, drug target identification, and clinical data sourcing, aiming to enhance drug discovery and clinical development processes. BioAI primarily serves the biopharma industry, leveraging AI to improve disease diagnosis and predict patient responses to therapies. It was founded in 2020 and is based in Manchester, New Hampshire.

Ibex specializes in AI-based cancer diagnostics within the healthcare technology sector. The company offers AI-powered diagnostic solutions that assist pathologists in providing accurate and efficient cancer diagnoses. Its solutions are developed using advanced algorithms and digital workflows to detect cancer with clinical-grade accuracy. It was founded in 2016 and is based in Tel Aviv, Israel.

Nucleai focuses on spatial biology in precision medicine. The company provides artificial intelligence (AI)-powered image analysis applications to pharmaceutical companies and clinicians, enhancing drug development and supporting treatment decisions. It primarily serves the pharmaceutical industry. It was founded in 2018 and is based in Chicago, Illinois.
Mechanomind provides AI diagnostics for skin cancer within the healthcare technology sector. The company utilizes computer vision and deep learning to assist in the diagnosis of skin cancer, including the classification of skin tumor subtypes and offering decision support for pathologists. Mechanomind's technology is scanner and image quality agnostic, aimed at maintaining accuracy and efficiency in histopathology analysis. It was founded in 2015 and is based in New York, New York.
Loading...